Xenon-anesthesia on patients undergoing major liver-resectio

Phase 1

• Conditions: post-resectional liver failure; Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]

• Registration Number: EUCTR2016-003684-19-DE
• Lead Sponsor: RWTH Aachen, represented by the Rector, himself represented by the Dean of the Medical Faculty

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-11-27
• Last Update Posted: 28 September 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

1.= 3 segment resection
2.= 18 years
3.Both gender
4.ASA I-III
5.Written informed consent prior to study participation

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 74
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 74

Exclusion Criteria

1.Severe pulmonary or airway disease
2.Severe liver disease, accompanied by a Child–Pugh class >A
3.Allergy/hypersensitivity to study medications
4.ASA > III
5.Patients susceptible to malignant hyperthermia
6.Women who are pregnant, breast-feeding or women of childbearing potential not using adequate contraceptive methods
7.Patients with elevated intracranial pressure
8.Patients legally unable to give written informed consent.
9.Patients with preeclampsia or eclampsia
10.Patients with a risk of high oxygen demand
11.Patients with seriously impaired cardiac function
12.All contraindications for xenon anesthesia according to the summary of product characteristics LENOXe
13. Patient participates in a parallel interventional clinical trial during this study or receives an investigational drug within 30 days prior to inclusion into this study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified